Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (EXPERRT Act)
The EXPERRT Act, or the Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012, was introduced in the House of Representatives on March 8 by Cystic Fibrosis Caucus co-chairs Reps. Ed Markey (D-MA), Tom Marino (R-PA), and Cliff Stearns (R-FL) and in the Senate on March 29 by Sen. Sheldon Whitehouse (D-RI).
If it becomes law, the EXPERRT Act will make it easier for the FDA to access the outside expertise they need to understand the science behind new drugs intended to treat cystic fibrosis and other rare diseases and subtypes of diseases.
By systematically collaborating with researchers, doctors, and other experts, FDA reviewers will be able to review breakthrough new treatments more efficiently and get them into the hands of patients.
How you can support the EXPERRT Act:
Explore the resources below to learn more about the EXPERRT Act.
Sign up to receive the CF Advocacy Newsletter and alerts.
If you have any questions, please email email@example.com.